荣昌生物(09995)今日盘中大幅下跌5.94%,引起市场关注。
消息面上,该公司近日与跨国药企艾伯维签署了关于双特异性抗体RC148的独家授权协议,潜在交易总额高达56亿美元。这一重大利好消息此前可能已推动股价上涨,今日的下跌或反映部分投资者选择获利了结。
根据协议,荣昌生物将获得6.5亿美元首付款,并有资格获得最高49.5亿美元的里程碑付款及销售分成。该交易彰显了公司创新药物的全球竞争力,但短期股价波动属正常市场反应。
荣昌生物(09995)今日盘中大幅下跌5.94%,引起市场关注。
消息面上,该公司近日与跨国药企艾伯维签署了关于双特异性抗体RC148的独家授权协议,潜在交易总额高达56亿美元。这一重大利好消息此前可能已推动股价上涨,今日的下跌或反映部分投资者选择获利了结。
根据协议,荣昌生物将获得6.5亿美元首付款,并有资格获得最高49.5亿美元的里程碑付款及销售分成。该交易彰显了公司创新药物的全球竞争力,但短期股价波动属正常市场反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.